Treatment of advanced colorectal cancer;Therapie des Metastasierten Kolorektalen Karzinoms

Gastroenterologe

Volumn 3, Issue 2, 2008, Pages 135-143

  Reinacher Schick, A ^a,b  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chemotherapy; Colorectal carcinoma; Liver metastases; Palliative treatment; Targeted therapy

Indexed keywords

EID: 43349092562     PISSN: 18619681     EISSN: 1861969X     Source Type: Journal    
DOI: 10.1007/s11377-008-0169-y     Document Type: Article

References (44)

1. 1. Aloia 2006 J Clin Oncol 24 4983 17075116 10.1200/JCO.2006.05.8156 1:CAS:528:DC%2BD28Xht1GnurzI Aloia T, Sebagh M, Plasse M et al. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983–4990
2. 2. Amado 2007 Eur J Cancer Suppl 5 8 10.1016/S1359-6349(07)70100-3 Amado RG, Wolf M, Freeman D et al. (2007) Analysis of K-ras mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur J Cancer Suppl 5: 8
3. 3. André 1999 J Clin Oncol 17 3560 10550155 André T, Bensmaine MA, Louvet C et al. (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560–3568
4. 4. Benoist 2006 J Clin Oncol 24 3939 16921046 10.1200/JCO.2006.05.8727 Benoist S, Brouquet A, Penna C et al. (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939–3945
5. 5. Cassidy J, Clarke S, Diaz-Rubio E et al. (2007) XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients withmetastatic colorectal cancer (MCRC). J Clin Oncol ASCO Annual Meeting Proceedings Part I. 25, No. 18S: 4030
6. 6. Cassidy J, Bjarnason GA, Hickish T et al. (2006) Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S: 3507
7. 7. Cunningham 2004 N Engl J Med 351 337 15269313 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345
8. 8. Douillard 2000 Lancet 355 1041 10744089 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D Douillard JY, Cunningham D, Roth AD et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041–1047
9. 9. Eng C, Maurel J, Scheithauer W et al. (2007) Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clinl Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S: 4003
10. 10. Folprecht 2005 Ann Oncol 16 1311 15870084 10.1093/annonc/mdi246 1:STN:280:DC%2BD2MzotFamsA%3D%3D Folprecht G, Grothey A, Alberts S et al. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311–1319
11. 11. Fong 1999 Ann Surg 230 309 10493478 10.1097/00000658-199909000-00004 1:STN:280:DyaK1MvitFahsw%3D%3D Fong Y, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predictingrecurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309–318; discussion 318–321
12. 12. Fuchs 2007 J Clin Oncol 25 4779 17947725 10.1200/JCO.2007.11.3357 1:CAS:528:DC%2BD2sXhtlCgsLbM Fuchs CS, Marshall J, Mitchell E et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779–4786
13. 13. Giantonio 2007 J Clin Oncol 25 1539 17442997 10.1200/JCO.2006.09.6305 1:CAS:528:DC%2BD2sXlsVyntbc%3D Giantonio BJ, Catalano PJ, Meropol NJ et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539–1544
14. 14. Goldberg 2004 J Clin Oncol 22 23 14665611 10.1200/JCO.2004.09.046 1:CAS:528:DC%2BD2cXpsVKitbY%3D Goldberg RM, Sargent DJ, Morton RF et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30
15. 15. Grothey 2004 J Clin Oncol 22 1209 15051767 10.1200/JCO.2004.11.037 1:CAS:528:DC%2BD2cXpsVGktLo%3D Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214
16. 16. Hecht 2008 Gastrointestinal Cancer Symposium 273 Hecht JR, Mitchell E, Chidiac T et al. (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/–panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Gastrointestinal Cancer Symposium: 273 (in press)
17. 17. Hurwitz 2004 N Engl J Med 350 2335 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
18. 18. Kabbinavar 2005 J Clin Oncol 23 3697 15738537 10.1200/JCO.2005.05.112 1:CAS:528:DC%2BD2MXlslWntr0%3D Kabbinavar FF, Schulz J, McCleod M et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697–3705
19. 19. Kohne 2002 Ann Oncol 13 308 11886010 10.1093/annonc/mdf034 1:STN:280:DC%2BD387ltl2nsg%3D%3D Kohne CH, Cunningham D, Di CF et al. (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308–317
20. 20. Koopman 2007 Lancet 370 135 17630036 10.1016/S0140-6736(07)61086-1 1:CAS:528:DC%2BD2sXns12jtLo%3D Koopman M, Antonini NF, Douma J et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370: 135–142
21. 21. Kowalski T, Maier C, Reinacher-Schick A, Schlegel U (in press) Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy: clinical features, pathophysiology and therapeutic options. Schmerz (Epub ahead of print)
22. 22. Maindrault-Goebel F, Lledo G, Chibaudel B et al. (2007) Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX inpatients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol Vol 25, No. 18S: 4013
23. 23. Masi 2004 Ann Oncol 15 1766 15550581 10.1093/annonc/mdh470 1:STN:280:DC%2BD2crotVGitg%3D%3D Masi G, Allegrini G, Cupini S et al. (2004) First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 15: 1766–1772
24. 24. Nordlinger B, Sorbye H, Collette L et al. (2007) Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S: LBA5
25. 25. O 2004 J Natl Cancer Inst 96 1420 10.1093/jnci/djh275 O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420–1425
26. 26. Rothenberg 2003 J Clin Oncol 21 2059 12775730 10.1200/JCO.2003.11.126 1:CAS:528:DC%2BD2cXpsVGqtL4%3D Rothenberg ML, Oza AM, Bigelow RH et al. (2003) Superiority of oxaliplatin and fluoruracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluoruracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059–2069
27. 27. Parks 2007 J Am Coll Surg 204 753 17481478 10.1016/j.jamcollsurg.2006.12.036 Parks R, Gonen M, Kemeny N et al. (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204: 753–761; discussion 761–763
28. 28. Porschen 2007 J Clin Oncol 25 4217 17548840 10.1200/JCO.2006.09.2684 1:CAS:528:DC%2BD2sXhtFyis7vK Porschen R, Arkenau HT, Kubicka S et al. (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217–4223
29. 29. Portier 2006 J Clin Oncol 24 4976 17075115 10.1200/JCO.2006.06.8353 1:CAS:528:DC%2BD28Xht1GnurzP Portier G, Elias D, Bouche O et al. (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24: 4976–4982
30. 30. Reinacher-Schick 2007 Internist 48 51 17160665 10.1007/s00108-006-1770-0 Reinacher-Schick AC, Bechstein WO (2007) Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology. Internist 48: 51–58
31. 31. Saltz 2000 N Engl J Med 343 905 11006366 10.1056/NEJM200009283431302 1:CAS:528:DC%2BD3cXntFOkt7Y%3D Saltz LB, Cox JV, Blanke C et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905–914
32. 32. Saltz LB, Clarke S, Diaz-Rubio E et al. (2007) Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-linemetastatic colorectal cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S: 4028
33. 33. Schmiegel 2004 Z Gastroenterol 42 1129 15508058 10.1055/s-2004-813699 1:STN:280:DC%2BD2crptVSlug%3D%3D Schmiegel W, Pox C, Adler G (2004) S3-Leitlinienkonferenz „Kolorektales Karzinom“. Z Gastroenterol 42: 1129–1177
34. 34. Schmiegel WH, Reinacher-Schick A, Freier W et al. (2007) Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): a randomized phase II study of the AIO GI tumor study group. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S: 4034
35. 35. Seymour 2007 Lancet 370 143 17630037 10.1016/S0140-6736(07)61087-3 1:CAS:528:DC%2BD2sXns12jtLs%3D Seymour MT, Maughan TS, Ledermann JA et al. (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370: 143–152
36. 36. Tournigand 2006 J Clin Oncol 24 394 16421419 10.1200/JCO.2005.03.0106 1:CAS:528:DC%2BD28XhsFSku7w%3D Tournigand C, Cervantes A, Figer A et al. (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24: 394–400
37. 37. Tournigand 2004 J Clin Oncol 15 229 Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 15: 229–237
38. 38. Van 2001 J Clin Oncol 19 4097 Van Cutsem E, Twelves C, Cassidy J et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097–4106
39. 39. Van Cutsem E, Nowacki M, Lang I et al. (2007) Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastaticcolorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S: 4000
40. 40. Van 2007 J Clin Oncol 25 1658 10.1200/JCO.2006.08.1620 1:CAS:528:DC%2BD2sXlvFyktLc%3D Van Cutsem E, Peeters M, Siena S et al. (2007) Open-label phase III trial of panitumumab plusbest supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664
41. 41. Adam 2004 Ann Surg 240 644 15383792 10.1097/01.sla.0000145964.08365.01 Adam R, Delvart V, Pascal E et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-termin survival. Ann Surg 240: 644–657
42. 42. Tannapfel A, Reinacher-Schick A (2008) Chemotherapieassoziierte Hepatoxizität in der Behandlung des kolorektalen Karzinoms (KRK). Z Gastronenterol (im Druck)
43. 43. Grothey 2004 J Clin Oncol 22 1209 15051767 10.1200/JCO.2004.11.037 1:CAS:528:DC%2BD2cXpsVGktLo%3D Grothey A, Sargent D, Golbbeg RM, Schmell HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-lencoroin, irrinotecan and oxaliplath in the course of treatment. J Clin Oncol 22: 1209–1214
44. 44. Tannapfel 2008 Pathologe 29 93 18210112 10.1007/s00292-007-0966-y 1:STN:280:DC%2BD1c7gtlejsw%3D%3D Tannapfel A (2008) Molecular pathology analysis of the KRAS mutation status in patient with metasasized colorectal carcinoma: an initial approach using predicitive pathology. Pathologe 29: 93–96